首页> 外文期刊>Autoimmunity >A novel 1,25-dihydroxyvitamin D-activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP).
【24h】

A novel 1,25-dihydroxyvitamin D-activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP).

机译:人肺泡巨噬细胞中的新型1,25-二羟基维生素D-激活素A通路在患有肺泡蛋白沉着症(PAP)的患者中功能异常。

获取原文
获取原文并翻译 | 示例
           

摘要

We have shown that activin A, a cytokine implicated in regulating B-cell proliferation, is severely deficient in alveolar macrophages from patients with pulmonary alveolar proteinosis (PAP), an autoimmune disorder characterized by surfactant accumulation and neutralizing autoantibodies to granulocyte-macrophage colony stimulating factor. Mechanisms of activin regulation in alveolar macrophages are not well understood. Based on previous gene array results from PAP bronchoalveolar lavage cells suggesting deficiencies in vitamin D target genes, and on recent evidence of vitamin D receptor elements (VDREs) in the human activin A gene promoter, we investigated the effects of 1,25-dihydroxyvitamin D (vitamin D(3)) on activin A expression in alveolar macrophages from healthy individuals and PAP patients. Activin A expression was stimulated by LPS in cultures of either healthy control or PAP alveolar macrophages; in contrast, vitamin D(3) increased activin A only in healthy controls but not in PAP. Compared to healthy controls, freshly obtained (uncultured) PAP alveolar macrophages displayed healthy intrinsic vitamin D receptor expression but deficient expression of vitamin D target genes, cathelicidin and thioredoxin interacting protein. PAP patients also demonstrated a relative insufficiency of circulating vitamin D. Investigation of activin A in murine alveolar macrophages confirmed a lack of functional response to vitamin D as anticipated since murine activin A does not contain VDREs. Results suggest that mechanisms of activin A deficiency in PAP alveolar macrophages may involve dysregulation of a novel species-specific vitamin D-activin A pathway.
机译:我们已经表明,激活素A(一种涉及调节B细胞增殖的细胞因子)严重缺乏来自肺泡蛋白沉着症(PAP)患者的肺泡巨噬细胞,肺泡巨噬细胞是一种以表面活性剂蓄积和中和粒状巨噬细胞集落刺激因子的中和自身抗体为特征的自身免疫性疾病。肺泡巨噬细胞中激活素调节的机制尚不清楚。基于以前的PAP支气管肺泡灌洗细胞基因阵列结果表明维生素D目标基因缺乏,并基于最近人类激活素A基因启动子中维生素D受体元素(VDREs)的证据,我们研究了1,25-二羟基维生素D的作用(维生素D(3))对健康个体和PAP患者肺泡巨噬细胞中激活素A表达的影响。 LPS在健康对照组或PAP肺泡巨噬细胞的培养物中激活蛋白A的表达。相反,维生素D(3)仅在健康对照组中增加激活素A,而在PAP中则没有。与健康对照相比,新鲜获得的(未培养的)PAP肺泡巨噬细胞显示出健康的固有维生素D受体表达,但维生素D目标基因,Cathelicidin和硫氧还蛋白相互作用蛋白的表达不足。 PAP患者还表现出循环维生素D的相对不足。对鼠肺泡巨噬细胞中活化素A的研究证实,由于鼠活化素A不包含VDRE,因此预期缺乏对维生素D的功能性反应。结果表明,PAP肺泡巨噬细胞中激活素A缺乏的机制可能涉及新的物种特异性维生素D-激活素A途径的失调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号